Equities

Eagle Pharmaceuticals Inc

Eagle Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.28
  • Today's Change-0.150 / -3.39%
  • Shares traded49.26k
  • 1 Year change-73.01%
  • Beta0.5403
Data delayed at least 15 minutes, as of Sep 18 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast

The one analyst offering a 12 month price target expects Eagle Pharmaceuticals Inc share price to rise to 17.00 in the next year from the last price of 4.28.
High297.2%17.00
Med297.2%17.00
Low297.2%17.00

Earnings history & estimates in USD

On Aug 08, 2023, Eagle Pharmaceuticals Inc reported 2nd quarter 2023 earnings of 1.18 per share. This result exceeded the 1.05 consensus of the 2 analysts covering the company and under-performed last year's 2nd quarter results by 24.36%.
Average growth rate-5.45%
Eagle Pharmaceuticals Inc reported annual 2022 earnings of 7.79 per share on Mar 13, 2023.
Average growth rate+44.25%
More ▼

Revenue history & estimates in USD

Eagle Pharmaceuticals, Inc. had 2nd quarter 2023 revenues of 64.65m. This bettered the 59.36m consensus of the 2 analysts covering the company. This was 44.21% below the prior year's 2nd quarter results.
Average growth rate-3.07%
Eagle Pharmaceuticals, Inc. had revenues for the full year 2022 of 316.61m. This was 84.56% above the prior year's results.
Average growth rate+15.90%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.